Clinical Trial Update: A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism [Phase 2]

View source ↗

Summary

Phase 2 trial update for recombinant human prourokinase in acute pulmonary embolism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• recombinant human prourokinase (recombinant human prourokinase)

Snippet

Sponsor: Tasly Biopharmaceuticals Co., Ltd. | Conditions: Acute Pulmonary Embolism | Phase 2 | Status: COMPLETED